1. Home
  2. RNAZ vs BYSI Comparison

RNAZ vs BYSI Comparison

Compare RNAZ & BYSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TransCode Therapeutics Inc.

RNAZ

TransCode Therapeutics Inc.

SELL

Current Price

$1.40

Market Cap

27.9M

Sector

Health Care

ML Signal

SELL

Logo BeyondSpring Inc.

BYSI

BeyondSpring Inc.

HOLD

Current Price

$0.56

Market Cap

25.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RNAZ
BYSI
Founded
2016
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
27.9M
25.5M
IPO Year
2021
2016

Fundamental Metrics

Financial Performance
Metric
RNAZ
BYSI
Price
$1.40
$0.56
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
17.7K
★ 134.9K
Earning Date
08-14-2026
11-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$49.96
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.30
$0.42
52 Week High
$12.60
$2.44

Technical Indicators

Market Signals
Indicator
RNAZ
BYSI
Relative Strength Index (RSI) 31.10 48.55
Support Level N/A $0.42
Resistance Level $1.93 $0.85
Average True Range (ATR) 0.15 0.12
MACD -0.02 0.01
Stochastic Oscillator 0.00 28.95

Price Performance

Historical Comparison
RNAZ
BYSI

About RNAZ TransCode Therapeutics Inc.

TransCode Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of RNA-based therapeutics and immuno-oncology treatments for cancer. The company's lead candidate, TTX-MC138, targets microRNA-10b and has completed a Phase 1a clinical trial, while it is also advancing additional product candidates, including a cancer vaccine and an oncolytic immunotherapy platform.

About BYSI BeyondSpring Inc.

BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment. Its first asset, Plinabulin is a novel brain-penetrant microtubule modulator with dendritic cell maturation and vasculature modulation mechanism, which has the potential to help mitigate acquired resistance from prior immune checkpoint inhibitors (ICI) treatment in cancer patients. It is a Selective Immunomodulating Microtubule-Binding Agent (SIMBA), which may provide multiple therapeutic opportunities.

Share on Social Networks: